早产儿呼吸窘迫综合征在进行肺表面活性物质替代治疗时,传统上需要机械通气,通过气管插管给药。但众所周知,机械通气和气管插管操作容易导致多种并发症的发生,如局部损伤出血、气胸、感染和支气管肺发育不良等。为了充分发挥肺表面活性...早产儿呼吸窘迫综合征在进行肺表面活性物质替代治疗时,传统上需要机械通气,通过气管插管给药。但众所周知,机械通气和气管插管操作容易导致多种并发症的发生,如局部损伤出血、气胸、感染和支气管肺发育不良等。为了充分发挥肺表面活性物质的效果,减少甚至避免机械通气和气管插管的不良影响,微创肺表面活性物质给药技术日益创新。这些技术包括气管插管–使用肺表面活性物质–拔管(INSURE)、咽部给药、喉罩给药、雾化吸入给药和侵入性较小的肺表面活性物质给药(LISA)等。其中,LISA已经得到了最广泛的研究,并有望作为一种对早产儿进行肺表面活性物质给药侵入性较小且有效的方式。现就微创肺表面活性物质给药技术研究进展作一综述。Traditionally, surfactant has been administered to preterm infants with respiratory distress syndrome by endotracheal tube after intubation and mechanical ventilation. However, it is well known that mechanical ventilation and endotracheal intubation can easily lead to a variety of complications, such as local injury bleeding, pneumothorax, infection, and bronchopulmonary dysplasia. In order to provide the benefits of surfactant and minimize the trauma caused by intubation and mechanical ventilation, several surfactant administration methods of less invasive have been developed. These techniques include INSURE (intubate-surfactant-extubate), pharyngeal administration, laryngeal mask administration, aerosolized surfactant administration, and less invasive surfactant administration (LISA). Of these, LISA has been studied extensively and holds the most promise as a less invasive and effective technique of surfactant administration to preterm infants. This article reviewed administration methods of minimally invasive surfactant technology in preterm infants with respiratory distress syndrome.展开更多
文摘早产儿呼吸窘迫综合征在进行肺表面活性物质替代治疗时,传统上需要机械通气,通过气管插管给药。但众所周知,机械通气和气管插管操作容易导致多种并发症的发生,如局部损伤出血、气胸、感染和支气管肺发育不良等。为了充分发挥肺表面活性物质的效果,减少甚至避免机械通气和气管插管的不良影响,微创肺表面活性物质给药技术日益创新。这些技术包括气管插管–使用肺表面活性物质–拔管(INSURE)、咽部给药、喉罩给药、雾化吸入给药和侵入性较小的肺表面活性物质给药(LISA)等。其中,LISA已经得到了最广泛的研究,并有望作为一种对早产儿进行肺表面活性物质给药侵入性较小且有效的方式。现就微创肺表面活性物质给药技术研究进展作一综述。Traditionally, surfactant has been administered to preterm infants with respiratory distress syndrome by endotracheal tube after intubation and mechanical ventilation. However, it is well known that mechanical ventilation and endotracheal intubation can easily lead to a variety of complications, such as local injury bleeding, pneumothorax, infection, and bronchopulmonary dysplasia. In order to provide the benefits of surfactant and minimize the trauma caused by intubation and mechanical ventilation, several surfactant administration methods of less invasive have been developed. These techniques include INSURE (intubate-surfactant-extubate), pharyngeal administration, laryngeal mask administration, aerosolized surfactant administration, and less invasive surfactant administration (LISA). Of these, LISA has been studied extensively and holds the most promise as a less invasive and effective technique of surfactant administration to preterm infants. This article reviewed administration methods of minimally invasive surfactant technology in preterm infants with respiratory distress syndrome.
